Last viewed:
IPHYF
Prices are updated after-hours
IPHYF
|
$2.65
104.6%
300
|
Health Technology
(0.0% 1d)
(13.2% 1m)
(-10.2% 1y)
(0.0% 2d)
(0.0% 3d)
(0.0% 7d)
(-62.5%
volume)
Earnings Calendar:
Market Cap: $ 204,779,375
http://www.innate-pharma.com/en
Sec
Filling
|
Patents
| n/a employees
(FR) Innate Pharma SA is a biopharmaceutical company. It focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
cancer
immunotherapy
antibody
t-cell
treatment
ceiling
cancer treatments
add to watch list
Paper trade
email alert is off
Press-releases
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Published: 2024-04-10
(Crawled : 09:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -1.65%
| O: -0.01%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -4.25%
| O: -0.32%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -9.62%
| O: -3.85%
H: 1.2%
C: 0.8%
iph45
pharma
drug
candidate
antibody
preclinical
Innate Pharma Announces Its Participation in Upcoming April 2024 Investor Conference
Published: 2024-04-09
(Crawled : 09:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -1.38%
| O: 0.28%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -3.83%
| O: -0.38%
H: 0.95%
C: 0.83%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -5.62%
| O: 2.57%
H: 1.81%
C: 1.81%
pharma
conference
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Published: 2024-04-05
(Crawled : 11:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -3.54%
| O: -1.77%
H: 0.0%
C: -1.81%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -6.35%
| O: -3.44%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -6.0%
| O: -0.4%
H: 0.0%
C: -5.22%
pharma
report
universal
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Published: 2024-03-21
(Crawled : 09:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -2.29%
| O: 0.14%
H: 0.24%
C: 0.24%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -3.83%
| O: 0.3%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -6.0%
| O: -4.51%
H: 4.25%
C: 0.96%
pharma
business
year
update
financial
results
Innate Pharma Announces Its Participation to Upcoming Investor Conference - March 19, 2024
Published: 2024-03-19
(Crawled : 08:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -2.31%
| O: -0.02%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -5.25%
| O: -1.51%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -1.67%
| O: 0.84%
H: 4.56%
C: 0.83%
pharma
conference
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
Published: 2024-03-14
(Crawled : 09:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -5.82%
| O: 0.23%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -6.0%
| O: -2.4%
H: 3.69%
C: 3.28%
pharma
conference
year
financial
results
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Published: 2024-03-06
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -1.01%
| O: 0.0%
H: 0.8%
C: 0.8%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -4.29%
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -8.56%
| O: 0.78%
H: 1.93%
C: 0.97%
iph6501
first
study
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Published: 2024-03-06
(Crawled : 11:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -1.01%
| O: 0.0%
H: 0.8%
C: 0.8%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -4.29%
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -8.56%
| O: 0.78%
H: 1.93%
C: 0.97%
iph45
pharma
drug
antibody
preclinical
Innate Pharma Announces Its Participation to Upcoming March 2024 Investor Conference
Published: 2024-02-21
(Crawled : 07:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -1.49%
| O: 1.7%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -3.99%
| O: -0.57%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -9.27%
| O: -2.32%
H: 0.0%
C: 0.0%
pharma
conference
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
Published: 2024-01-12
(Crawled : 11:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -11.92%
| O: 0.71%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -13.05%
| O: 0.06%
H: 0.0%
C: 0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
| -15.77%
| O: 0.0%
H: 0.36%
C: 0.36%
pharma
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount